Analyzing Morgan Stanley Direct Lending Fund (NYSE:MSDL) and Advanced Medical Isotope (OTCMKTS:RDGL)

Advanced Medical Isotope (OTCMKTS:RDGL) and Morgan Stanley Direct Lending Fund (NYSE:MSDL) are both small-cap finance companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership.

Profitability

This table compares Advanced Medical Isotope and Morgan Stanley Direct Lending Fund’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Advanced Medical Isotope	-6,144.90%	N/A	-113.56%
Morgan Stanley Direct Lending Fund	35.92%	10.21%	4.70%

Valuation and Earnings

This table compares Advanced Medical Isotope and Morgan Stanley Direct Lending Fund”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Advanced Medical Isotope	$30,000.00	1,076.05	-$2.91 million	N/A	N/A
Morgan Stanley Direct Lending Fund	$416.08 million	3.71	$215.56 million	$1.65	10.79

Morgan Stanley Direct Lending Fund has higher revenue and earnings than Advanced Medical Isotope.

Analyst Ratings

This is a summary of current recommendations and price targets for Advanced Medical Isotope and Morgan Stanley Direct Lending Fund, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Advanced Medical Isotope	0	0	0	0	0.00
Morgan Stanley Direct Lending Fund	0	5	2	0	2.29

Morgan Stanley Direct Lending Fund has a consensus target price of $17.75, suggesting a potential downside of 0.31%. Given Morgan Stanley Direct Lending Fund’s stronger consensus rating and higher possible upside, analysts clearly believe Morgan Stanley Direct Lending Fund is more favorable than Advanced Medical Isotope.

Risk and Volatility

Advanced Medical Isotope has a beta of -0.39, meaning that its share price is 139% less volatile than the S&P 500. Comparatively, Morgan Stanley Direct Lending Fund has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500.

Summary

Morgan Stanley Direct Lending Fund beats Advanced Medical Isotope on 9 of the 10 factors compared between the two stocks.

About Advanced Medical Isotope

Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington.

About Morgan Stanley Direct Lending Fund

Morgan Stanley Direct Lending Fund is a business development company. It is a non-diversified, externally managed specialty finance company focused on lending to middle-market companies. Morgan Stanley Direct Lending Fund is based in NEW YORK.